Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01271283
First received: January 5, 2011
Last updated: September 23, 2013
Last verified: September 2013

January 5, 2011
September 23, 2013
December 2010
September 2011   (final data collection date for primary outcome measure)
Time to progression [ Time Frame: From the start of lenalidomide therapy to time of disease progression, assessed up to 24 months ] [ Designated as safety issue: No ]
Time to progression (at 24 months) in patients with high-risk CLL treated with lenalidomide [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01271283 on ClinicalTrials.gov Archive Site
Maximal clinical response (complete and partial response) [ Time Frame: Up to 24 months ] [ Designated as safety issue: No ]
Summarized by a sample proportion along with the exact 95% confidence interval. The time-to-progression will be graphically analyzed using standard Kaplan-Meier estimation.
  • Maximal clinical response (complete and partial response) [ Designated as safety issue: No ]
  • Incidence of immune-mediated flare reaction [ Designated as safety issue: No ]
  • Adverse events [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia
Lenalidomide for the Treatment of CLL Patients With High-Risk Disease

This phase II clinical trial is studying how well lenalidomide works in treating patients with high-risk chronic lymphocytic leukemia. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing.

PRIMARY OBJECTIVES:

I. To determine the time to progression in patients with high-risk chronic lymphocytic leukemia (CLL) treated with lenalidomide.

SECONDARY OBJECTIVES:

I. To determine the clinical response (complete and partial response) in treatment-naïve patients with high-risk CLL treated with single-agent lenalidomide.

II. To determine the incidence of immune-mediated flare reaction. III. To determine the toxicity profile of single-agent lenalidomide in previously untreated patients with high-risk CLL.

IV. To conduct correlative studies in bone marrow, peripheral blood, and/or lymph nodes of patients treated with lenalidomide.

OUTLINE:

Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (by morphological criteria but have persistent minimal residual disease by molecular criteria) or partial response may continue treatment beyond 8 courses. Patients may undergo bone marrow, peripheral blood, and/or lymph node sample collection at baseline and periodically during study for correlative studies.

After completion of study therapy, patients are followed up every 3 months for a maximum of 5 years.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • B-cell Chronic Lymphocytic Leukemia
  • Stage III Chronic Lymphocytic Leukemia
  • Stage IV Chronic Lymphocytic Leukemia
  • Drug: lenalidomide
    Given orally
    Other Names:
    • CC-5013
    • IMiD-1
    • Revlimid
  • Other: diagnostic laboratory biomarker analysis
    Correlative studies
Experimental: Arm I
Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (by morphological criteria but have persistent minimal residual disease by molecular criteria) or partial response may continue treatment beyond 8 courses. Patients may undergo bone marrow, peripheral blood, and/or lymph node sample collection at baseline and periodically during study for correlative studies.
Interventions:
  • Drug: lenalidomide
  • Other: diagnostic laboratory biomarker analysis
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
49
Not Provided
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Definitive diagnosis of B-cell chronic lymphocytic leukemia (B-CLL) as defined by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria

    • Must have high-risk B-CLL as defined by ≥ one of the following:

      • High-risk cytogenetics (either 17p deletion and/or 11q deletion)
      • Unmutated immunoglobulin heavy chain gene rearrangement
    • Zap-70 and CD38 expression on leukemic cells will not be used as eligibility criteria for enrollment into the clinical trial
  • No prior treatment for the management of B-CLL
  • Patients must have B-CLL requiring therapy as defined by the IWCLL criteria
  • Must have measurable disease meeting one of the following criteria:

    • Absolute lymphocyte count > 5,000/μL
    • Measurable lymphadenopathy or organomegaly
  • No tumor lysis syndrome (TLS) by Cairo-Bishop definition

    • Patients with correction of electrolyte abnormalities allowed
  • ECOG performance status 0-2
  • ANC ≥ 1,500/mm³
  • Platelet count ≥ 75,000/mm³
  • Creatinine clearance ≥ 30 mL/min
  • Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • AST and ALT ≤ 3 times ULN (≤ 5 times ULN if hepatic metastases are present)
  • Uric acid normal

    • Patients with elevated uric acid allowed provided it is corrected with appropriate pharmacologic measures
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must commit to continued abstinence from heterosexual intercourse or use 2 acceptable methods of contraception (1 highly effective method and 1 additional effective method) ≥ 28 days prior to, during, and for ≥ 28 days after discontinuing lenalidomide
  • Able to adhere to the study visit schedule and other protocol requirements
  • No serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from signing the informed consent form
  • No condition, including the presence of laboratory abnormalities, that would place the patient at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
  • No known hypersensitivity to thalidomide or lenalidomide
  • No history of erythema nodosum characterized by a desquamating rash while taking thalidomide or similar drugs
  • No history of any other cancer except non-melanoma skin cancer or carcinoma in-situ of the cervix or cancer for which the patient is in complete remission and off therapy for > 3 years
  • No cardiac arrest within the past 6 months
  • No known history of hepatitis B infection, positive hepatitis B surface antigen, or positive hepatitis C antibody
  • No other concurrent anti-cancer agents or treatments
  • More than 28 days since any prior experimental drug or therapy
  • Aspirin (81 or 325 mg) or warfarin sodium daily as prophylactic anticoagulation required
  • No prior lenalidomide
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01271283
NCI-2011-02568, NCI-2011-02568, CDR0000692070, RPCI # I 174910, 8254
Not Provided
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Asher Chanan-Khan Roswell Park Cancer Institute
National Cancer Institute (NCI)
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP